Metabolic Disorders
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Metabolic Disorders market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Metabolic Disorders market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Tumor Lysis Syndrome Global Clinical Trials Review, H2, 2018 Tumor Lysis Syndrome Global Clinical Trials Review, H2, 2018
$2,500 | September 2018 GlobalData's clinical trial report, “Tumor Lysis Syndrome Global Clinical Trials Review, H2, 2018" provides an overview of Tumor Lysis Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Tumor Lysis Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H2, 2018 Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H2, 2018
$2,500 | September 2018 GlobalData's clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H2, 2018" provides an overview of Type 1 Diabetes (Juvenile Diabetes) clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2018 Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2018
$2,500 | May 2018 GlobalData's clinical trial report, “Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2018" provides an overview of Pre-Diabetes/Impaired Glucose Tolerance clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Osteoporosis: Global Drug Forecast and Market Analysis to 2027 Osteoporosis: Global Drug Forecast and Market Analysis to 2027
$14,995 | April 2018 Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a natural process known as remodeling, some of the bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures. Osteoporosis is often referred to as a “silent”...
-
Sector Analysis
PharmaPoint: Painful Diabetic Neuropathy - Global Drug Forecast and Market Analysis to 2026 PharmaPoint: Painful Diabetic Neuropathy - Global Drug Forecast and Market Analysis to 2026
$14,995 | January 2018 Painful diabetic neuropathy is a late-stage complication that occurs in patients suffering from diabetes mellitus and is thought to affect up to half of patients with the disease. PDN manifests itself as a variety of syndromes which differ in clinical course, distribution, fibre involvement and, pathophysiology. Symptoms will vary from patient to patient however; the most common pain symptoms are reported to be numbness, tingling, burning, sharp, and dull/ache-like, which are often localized to the extremities, affecting the feet and...
-
Sector Analysis
Osteoporosis – Global Drug Forecast and Market Analysis to 2027 Osteoporosis – Global Drug Forecast and Market Analysis to 2027
$14,995 | March 2019 Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a natural process known as remodeling, some of the bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures. Osteoporosis is often referred to as a “silent”...
-
Sector Analysis
Pompe Disease: Opportunity Analysis and Forecasts to 2027 Pompe Disease: Opportunity Analysis and Forecasts to 2027
$10,995 | November 2018 Pompe disease (PD) is a rare genetic disorder resulting in the accumulation of glycogen with lysosomes in various tissues of the body. It is caused by a multitude of different phenotypical mutations to the GAA gene which is responsible for the transcription of α-glucosidase. α-glucosidase is responsible for glycogen degradation through enzymatic cleavage. PD is characterized by two types: infantile-onset Pomp disease (IOPD) and late-onset Pompe disease (LOPD). IOPD tends to be caused a severe deficiency or entire absence of...
-
Sector Analysis
Diabetic Macular Edema Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031 Diabetic Macular Edema Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
$14,995 | August 2022 The Diabetic Macular Edema market size was $5.05 billion in 2021 across the 7MM (seven major pharmaceutical markets). The market is forecast to achieve a CAGR of more than 8% during the forecast period. Diabetic Macular Edema is a complication of type 1 and 2 diabetes with diabetic retinopathy. It is a leading cause of visual impairment and blindness in first-world countries, affecting over 28 million people (International Diabetes Federation, 2016; de Moura et al., 2020). The DME research report...
-
Sector Analysis
PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025 PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2025
$14,995 | June 2016 The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. We anticipate that the...
-
Sector Analysis
Hypoglycemia Drug Market Size, Company Share, Trends Analysis and Forecast 2021-2030 Hypoglycemia Drug Market Size, Company Share, Trends Analysis and Forecast 2021-2030
$14,995 | November 2021 The hypoglycemia drug sales have been valued to $423.5 million across the 7MM in 2020 growing at a CAGR of more than 4%. The US has contributed more than 90% of the sales that is primarily due to the significantly higher prices of glucagons in the US, a relatively high diagnosed prevalence of type 1 diabetes (T1D) and high incidence rate of post-bariatric hypoglycemia (PBH). The next largest individual markets are Italy and Germany. Therefore, altogether the 5EU countries make...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.